BD (NYSE: BDX) announced today that it plans to invest more than $35 million in U.S.-based prefilled flush syringe manufacturing.
The company expects to add approximately 50 new jobs, expanding the manufacturing at its Columbus, Nebraska, facility. BD says it aims to increase the resiliency of the U.S. healthcare system through its latest syringe manufacturing investment.
Earlier this year, the company added more capacity to its U.S. syringe manufacturing operations, among other product lines. It continues to bulk up the U.S. operations after, in 2024, it increased capacity after the FDA issued warnings related to syringes manufactured in China. Then, BD installed new needle and syringe production lines at plants in Connecticut and Nebraska.
The latest investments support the PosiFlush prefilled syringe production lines, product innovation and operational efficiencies. BD expects to produce hundreds of millions of additional units annually to meet growing demand from U.S. hospitals and health systems. It comes as part of a planned $2.5 billion investment in U.S. manufacturing capacity over the next five years.
PosiFlush syringes serve as part of catheter care and maintenance to help prevent catheter-related complications. They are manufactured using a fully automated, hands-free process. This ensures that the first person to touch the syringe is the clinician, reducing the risk of contamination. Over the past three years, BD’s investment in the product’s capacity expansion totals more than $80 million.
“BD PosiFlush syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications,” said Eric Borin, worldwide president of BD Medication Delivery Solutions. “Our latest investments boost U.S. production capacity and reinforce our commitment to a reliable supply for health care providers and the patients they serve.”
